Janssen Announces U.S. FDA Approval of SYMTUZA ™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 17, 2018 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of SYMTUZATM (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 17, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports 2018 Second-Quarter Results:
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 17, 2018 Category: Pharmaceuticals Source Type: news

Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA ® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 16, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2018
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 16, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA Extends Review Timeline for INVOKANA ® (canagliflozin) Supplemental New Drug Application
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 13, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson ’s Official Statement in Response to Today’s Verdict in St. Louis Trial
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 13, 2018 Category: Pharmaceuticals Source Type: news

Janssen Provides Update on IMBRUVICA ® (ibrutinib) Phase 3 PHOENIX Trial in Newly Diagnosed Non-Germinal Center B Cell (Non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 11, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Publication in The Lancet Highlighting Robust Immune Response to Janssen ’s Mosaic-based Preventive Vaccine Regimen for HIV
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 6, 2018 Category: Pharmaceuticals Source Type: news

Champions of Science: The Art of Ending Stigma Project Launches to Combat Stigma About Mental Illnesses Through Education and Artistic Creation
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 26, 2018 Category: Pharmaceuticals Source Type: news

Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA ® (canagliflozin) Compared to Other Diabetes Medications
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 24, 2018 Category: Pharmaceuticals Source Type: news

Real-World Evidence Shows Oral INVOKANA ® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 23, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Retirement of Group Worldwide Chairman, Sandra E. Peterson
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 22, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Appoints Senior Leaders to Executive Committee
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 22, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 19, 2018 Category: Pharmaceuticals Source Type: news

Janssen Phase 3 Study Programme of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Presented for the First Time in Europe
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 19, 2018 Category: Pharmaceuticals Source Type: news

XARELTO ® (rivaroxaban) Associated with Significantly Reduced Time in Hospital and Decreased Costs Compared to Standard of Care in New Study of Patients with Low-Risk Pulmonary Embolism (PE)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 14, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc.
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 13, 2018 Category: Pharmaceuticals Source Type: news

New Late-Breaking Data on the Use of Type 2 Diabetes Treatment INVOKANA ® (canagliflozin) in the Real World Will Be Presented at the American Diabetes Association’s 78th Annual Scientific Sessions
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 8, 2018 Category: Pharmaceuticals Source Type: news

DePuy Synthes Launches Innovative Nailing System Aimed at Improving Treatment of Femoral Shaft Fractures in the U.S.
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 7, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Binding Offer from Fortive Corporation to Acquire Advanced Sterilization Products (ASP)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 7, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Progress Toward Health for Humanity Goals
Annual Health for Humanity Report Discloses Progress on Global Commitments and Highlights Key Achievements Toward Eradicating and Preventing Disease, Reimagining Care Delivery and Promoting Lifelong Health (Source: Johnson and Johnson)
Source: Johnson and Johnson - June 5, 2018 Category: Pharmaceuticals Source Type: news

James Allison, Ph.D., Wins 2018 Dr. Paul Janssen Award for Biomedical Research
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 5, 2018 Category: Pharmaceuticals Source Type: news

Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 3, 2018 Category: Pharmaceuticals Source Type: news

IMBRUVICA ® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström’s Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin’s Lymphoma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 2, 2018 Category: Pharmaceuticals Source Type: news

Long-Term Phase 3 Study Shows Esketamine Nasal Spray Plus an Oral Antidepressant Delayed Time to Relapse in Patients with Treatment-Resistant Depression
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 31, 2018 Category: Pharmaceuticals Source Type: news

Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 30, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 29, 2018 Category: Pharmaceuticals Source Type: news

New Study Is First to Find Short, Intensive Workplace Wellness Intervention Provided Improvements in Employee Vitality and Purpose in Life
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 29, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the Jefferies 2018 Global Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 24, 2018 Category: Pharmaceuticals Source Type: news

New Real-World Study Finds Long-Term XARELTO ® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 24, 2018 Category: Pharmaceuticals Source Type: news

Cerenovus receives fda clearance for next generation stent retriever device used to treat ischemic stroke
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 21, 2018 Category: Pharmaceuticals Source Type: news

Janssen Announces European Commission Approval of JULUCA ®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 21, 2018 Category: Pharmaceuticals Source Type: news

ERLEADA ™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 19, 2018 Category: Pharmaceuticals Source Type: news

Janssen to Present New Data in Urothelial, Hematologic and Prostate Cancers at ASCO 2018, Including Best of ASCO Selections
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 17, 2018 Category: Pharmaceuticals Source Type: news

Biosense webster, inc launches sheath designed to reduce radiation exposure and improve ablation procedure efficiency
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 9, 2018 Category: Pharmaceuticals Source Type: news

Janssen Announces DARZALEX ® (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 8, 2018 Category: Pharmaceuticals Source Type: news

New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 5, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the 2018 UBS Global Health Care Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 3, 2018 Category: Pharmaceuticals Source Type: news

Janssen to Present Data in Treatment-Resistant Depression, Schizophrenia, Health Economics and Outcomes and Population Health at American Psychiatric Association 2018 Meeting
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 3, 2018 Category: Pharmaceuticals Source Type: news

Biosense webster, inc. launches study to evaluate novel high power, short duration modality for treatment of atrial fibrillation
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 3, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Host Consumer and Medical Devices Business Review
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 2, 2018 Category: Pharmaceuticals Source Type: news

Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 2, 2018 Category: Pharmaceuticals Source Type: news

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT ® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 30, 2018 Category: Pharmaceuticals Source Type: news

Real-World Study Shows INVOKANA ® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 27, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Dividend Increase of 7.1%
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 26, 2018 Category: Pharmaceuticals Source Type: news

New PROTI 360 ° Family of Implants from DePuy Synthes Is Designed to Enhance Spinal Fusion Surgery Outcomes
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 26, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 25, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports 2018 First-Quarter Results
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 17, 2018 Category: Pharmaceuticals Source Type: news

Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 17, 2018 Category: Pharmaceuticals Source Type: news